Because of their cytotoxic activity and release of soluble factors [16] , it is thought that CD8+ T cells play an important role in tumor control. We recently showed that IFN-gamma production by CD8+ T cells from gastric cancer patients is suppressed and that this suppression is closely related to decreased expression of the immunoreceptor NKG2D [17] . Thus, CD8+ T cells may be one of the main targets for immune evasion by gastric cancer cells. We evaluated the expression of PD-1 and Tim-3 on CD8+ T cells to analyze the correlation between the expression of those molecules and the function of CD8+ T cells.
Methods

Patients and healthy donors
The subjects of this study were 53 patients (38 men and 15 women; mean age, 69.7 ± 9.7 years), with pathologically diagnosed gastric adenocarcinoma, who were treated at Tottori University Hospital between November, 2010 and March, 2012. None of these patients received radiotherapy, chemotherapy, or other medical interventions before surgery. Their clinicopathological characteristics were defined according to the Japanese Classification of Gastric Carcinoma [18] . This study also enrolled 28 age-matched healthy controls (18 men and 10 women), with a mean age of 65.0 ± 8.1 years. All patients and controls provided written informed consent, and the study protocol was approved by the Institutional Review Board at Tottori University Hospital (Yonago, Japan).
Preparation of peripheral blood mononuclear cells (PBMCs)
A 30-ml aliquot of peripheral blood was collected from each patient prior to surgery and from each control subject. All samples were centrifuged through a Ficoll-Paque (Pharmacia, Uppsala, Sweden) gradient.
Isolation of tumor infiltrating lymphocytes (TILs)
Freshly excised tumor tissues were minced and digested with 1.5 mg/ml of collagenase D (Wako Pure Chemical Industries Ltd., Osaka, Japan) for 20 min. The resulting cell suspensions were filtered through a mesh filter (BD, Franklin Lakes, NJ, USA) and washed twice in phosphate-buffered saline containing 1 % bovine serum albumin.
Flow cytometry analysis
Fluorescence-activated cell sorting (FACS) analysis was performed using a FACSCalibur™ flow cytometer (BD). Briefly, cell suspensions (1 × 10 6 to 2 × 10 6 ) were incubated with anti-CD3-PE-Cy5, anti-CD8-FITC, anti-PD-1-PE (BD PharMingen, Franklin Lakes, NJ, USA), and anti-Tim-3-PE (R&D Systems, Minneapolis, MN, USA) antibodies in the dark for 30 min, washed twice in 2 ml phosphate-buffered saline containing 1 % bovine serum albumin and 0.01 % sodium azide, and subsequently fixed in 200 µl of stabilizing fixative (BD). Isotype-matched control antibodies were used to establish background levels of staining.
Measurement of interferon (IFN)-gamma concentrations
CD4+ or CD8+ T cells were sorted based on PD-1 and Tim-3 expression. Each population was seeded at 1 × 10 4 cells/well in anti-CD3 antibody-coated 96-well plates (Nunc A/S, Roskilde, Denmark). After 48 h, the supernatants were collected, and their IFN-gamma concentrations were measured by enzyme-linked immunosorbent assay (ELISA) using a human IFN-gamma ELISA Kit (R&D Systems) according to the manufacturer's instructions.
Cell culture
Cells were cultured in complete medium, consisting of RPMI 1640, 1 % l-glutamine, 1 % penicillin/streptomycin, 2.5 % HEPES buffer solution (all from Life Technologies, Foster City, CA, USA), 1 % sodium pyruvate (SigmaAldrich, St. Louis, MO, USA), 1 % essential amino acids (Sigma-Aldrich), and 10 % human AB serum (Gemini BioProducts, Woodlands, CA, USA).
Statistical analysis
Paired t tests or Mann-Whitney U tests were used to calculate significance and the Bonferroni correction was used to perform multiple comparisons. Correlations were analyzed by the Spearman rank correlation coefficient test. GraphPad Prism software (GraphPad Software Inc., La Jolla, CA, USA) and SPSS statistical software (IBM SPSS, Chicago, IL, USA) were used for all statistical analyses, with p < 0.05 considered significant.
Results
Increased population of PD-1+ and Tim-3+ CD8+ T cells in the peripheral blood of gastric cancer patients
Assays of PD-1 and Tim-3 expression on circulating CD8+ T cells showed a significantly higher population of PD-1+ and Tim-3+ CD8+ T cells in the gastric cancer patients than in the controls, at 14.5 ± 8.0 vs. 10.5 ± 6.0 % (p = 0.043; Fig. 1 ) and 1.6 ± 1.3 vs. 0.69 ± 0.62 % (p < 0.0001; Fig. 2 ), respectively. Moreover, the number of PD-1+ and Tim-3+ CD8+ T cells showed a significant positive correlation (r = 0.29, p = 0.036; Fig. 3 ).
Increased population of PD-1+ and Tim-3+ CD8+ T cells in gastric cancer tissue
Analysis of PD-1 and Tim-3 expression on CD8+ T cells in the gastric cancer tissue from these patients revealed significantly higher levels of both PD-1+ and Tim-3+ CD8+ T cells, at 43.1 ± 25.1 vs. 12.5 ± 7.1 % (p = 0.0003, Fig. 4 ) and 12.0 ± 12.5 vs. 1.4 ± 1.5 % (p = 0.0026, Fig. 5 ), respectively, in the gastric cancer tissue than in PBMCs.
PD-1 and Tim-3 expression is related to the impairment of CD8+ T cell function in gastric cancer
To assess the effect of PD-1 and Tim-3 expression on CD8+ T cell function in gastric cancer patients, we analyzed the secretion of IFN-gamma by these cells. Cells positive for both PD-1 and Tim-3 positive produced significantly less IFN-gamma than cells negative for both and cells positive for PD-1 and negative for Tim-3 (Fig. 6 ).
Discussion
Co-signaling molecules are cell-surface glycoproteins that can direct, modulate and fine-tune T cell receptor (TCR) signals. Based on their functional outcomes, co-signaling molecules can be divided into co-stimulators and co-inhibitors, which promote or suppress T-cell activation, respectively. The expression of these molecules at the appropriate time and location positively and negatively controls the priming, growth, differentiation, and functional maturation of T-cell responses [4] . close proximity to the TCR signaling complex, delivers a co-inhibitory signal [19] . The PD-1 pathway is important for maintaining peripheral T cell tolerance. Tim-3 is a transmembrane protein constitutively expressed on Th1/Tc1 cells in mice and humans [20] . Tim-3 acts as an inhibitory molecule that down-regulates effector Th1/Tc1 cell responses. Blocking the Tim-3-Tim-3L pathway in mice resulted in hyperproliferation of Th1-type cells and abrogated the induction of peripheral and transplantation tolerance [21, 22] . Tim-3 interacts with its ligand, galectin-9, to induce cell death of Th1 cells [23] .
In humans, Tim-3 expression is defective in CD4+ T cells producing high levels of IFN-gamma, as well as in CD4+ T cells isolated from the cerebrospinal fluid of patients with multiple sclerosis [24] .
Chronic infections have exploited the PD-1 and Tim-3 pathways to evade eradication by the immune system. In fact, exhausted antigen-specific CD8+ T cells have been observed in patients chronically infected with HIV, HBV, and HCV. These exhausted virus-specific T cells express high levels of PD-1 and Tim-3 [15, 25, 26] . Although a few papers describe the relationship between PD-1 and Tim-3 expression and the dysfunction of T cells in cancer patients, it is still poorly understood in gastric cancer patients.
In the present study, we examined PD-1 and Tim-3 expression on CD8+ T cells obtained from gastric cancer patients as a first step towards evaluating the correlations between the expression of immune-checkpoint proteins and immune evasion in gastric cancer. The population of PD-1+ and Tim-3+ CD8+ T cells in peripheral blood was significantly greater in gastric cancer patients than in healthy controls. Moreover, we found that up-regulation of PD-1 and Tim-3 expression was closely associated with the functional properties of these CD8+ T cells. Cells positive for both PD-1 and Tim-3 produced significantly less IFNgamma than cells negative for both molecules and those positive for PD-1 and negative for Tim-3.
The mechanisms responsible for the upregulation of PD-1 and Tim-3 in gastric cancer remain unclear. Upregulation of PD-1 on CD8+ T cells was found to be associated with IL-10 and IL-6, but not TGF-beta. We previously reported that serum IL-6 concentrations were significantly higher in gastric cancer patients than in healthy controls [27] and that gastric cancer cells produce IL-10 [28] . This study showed a significant positive correlation between PD-1+ and Tim-3+ CD8+ T cells in peripheral blood, suggesting the possibility that the same factors upregulate both. Additionally, we observed a higher population of PD-1+ and Tim-3+ CD8+ T cells in the gastric cancer tissue than in the peripheral blood from gastric cancer patients. These findings suggest that the tumor cells themselves may affect PD-1 and Tim-3 expression in gastric cancer. Further investigations are warranted to clarify the mechanisms responsible for PD-1 and Tim-3 upregulation in gastric cancer.
Regulatory pathways that limit the immune response to cancer have attracted attention as important targets for immunotherapy. For example, cytotoxic T-lymphocyteassociated antigen 4 (CTLA-4) was found to down-regulate T-cell activation pathways [29] and ipilimumab, a fully human monoclonal antibody (IgG1) that blocks CTLA-4, was recently shown to promote antitumor immunity and to improve the overall survival of patients with previously treated metastatic melanoma [30] . Anti-PD-1 antibodies, Population of Tim-3 positive CD8+ T cell (%) p=0.00026 such as nivolumab and pembrolizumab were also shown to improve prognosis in melanoma [31, 32] and lung cancer [33] . Furthermore, Postow et al. more recently demonstrated that the objective-response rate and progression-free survival of patients with advanced melanoma who had not previously received treatment were significantly greater with nivolumab combined with ipilimumab than with ipilimumab monotherapy, indicating that the addition of another immune-checkpoint inhibitor to the PD-1 checkpoint inhibitor helps to control tumor growth [34] . Because PD-1 and Tim-3 expression on CD8+ T cells is upregulated in gastric cancer, immunotherapy targeting PD-1 and Tim-3 may provide a breakthrough in the treatment of gastric cancer.
